Dialysis patients who have been subjected to PCI.
Conditions
Interventions
Patients treated with eicosapentaenoic acid (EPA), who were treated with 1800 mg/day of a highly purified EPA preparation in addition to conventional therapy.
Conventional therapy.
Sponsors
Nagoya Kyoritsu Hospital
Department of Cardiology, Nagoya University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Dialysis patients who exhibited stenosis in excess of 75%, involving 1 to 2 branches noted by means such as coronary angiography and have stenting by using percutaneous coronary intervention (PCI). 2) Over 20 and under 75 years of age. 3) Available for a 12-month follow-up after PCI. 4) Have given their consent in written form.
Exclusion criteria
Exclusion criteria: 1) A history of hypersensitivity to highly purified EPA preparations. 2) Have had the onset of stroke within the past 6 months. 3) Left ventricular ejection fraction below 40%. 4) Are currently pregnant or may be pregnant. 5) Suffering from hemorrhage (e.g., hemophilia, capillary fragility, gastrointestinal hemorrhage, urinary tract hemorrhage, hemoptysis and vitreous hemorrhage). 6) A peptic ulcer. 7) Extremely poor bile secretion or severe hepatic dysfunction. 8) Others judged to be inappropriate to participate in the current study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Restenosis rate one year after the treatment TVR one year after the treatment MACE [death, non-fatal myocardial infarction, stroke, revascularization (endovascular treatment or bypass surgery)] | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in IMT and CAVI as seen in comparison with before and after EPA administration | — |
Countries
Japan
Contacts
Public ContactDaisuke Kamoi
Nagoya Kyoritsu Hospital Department of Cardiology
Outcome results
None listed